S&P Futures
4,111.75-7.75(-0.19%)Dow Futures
33,582.00-100.00(-0.30%)Nasdaq Futures
13,821.75-7.75(-0.06%)
Conformis, Inc. (CFMS)
0.8907 -0.01 (-0.72%)
Pre-Market: 4:12AM EDT
Chart Events
Performance Outlook
| Previous Close | 0.8983 |
| Open | 0.8907 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.8833 - 0.9254 |
| 52 Week Range | 0.6020 - 1.4900 |
| Volume | 1,635,367 |
| Avg. Volume | 5,742,727 |
| Market Cap | 163.81M |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3400 |
| Earnings Date | May 05, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- GlobeNewswire
Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021
BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Wednesday, May 5, 2021, at 4:30 p.m. Eastern Time to discuss the financial results and to provide a business update. The webcast will be live at: https://edge.media-server.com/mmc/p/vnzdh2h9. To attend by telephone, please use the information below for dial-in access. When prompted on dial-in, please utilize conference ID: 8727027.Participant conference numbers (877) 809-6331 (U.S./Canada) and (615) 247-0224 (International).Please dial in at least 10 minutes before the call to ensure timely participation. Please visit the Investor Relations website at ir.conformis.com on May 5, 2021 to view the earnings release prior to the webcast and conference call. The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient's unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/. CONTACT: Contact Investor Contact: Investor Relations ir@conformis.com (781) 374-5598
- Zacks
Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System
Orthofix's (OFIX) CONSTRUX Mini Ti Spacer System, designed with nanoscale surface is the first 3D-printed titanium interbody, was launched to enhance ACDF procedures.
- Zacks
Varian Medical (VAR) Hits 52-Week High: What's Driving It?
Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.
